Marquis®
The first FDA-approved EPM treatment combining safety, efficacy and convenience.
Key Benefits
Product performance that offers new hope:
- Marquis (15% w/w ponazuril) Antiprotozoal Oral Paste offers proven efficacy against equine protozoal myeloencephalitis (EPM).
- The active ingredient is ponazuril, an anticoccidial compound with cidal activity against Sarcocystis neurona, the protozoal parasite that causes equine protozoal myeloencephalitis (EPM).
- Ponazuril acts against the parasite at several stages of the lifecycle.
- Ponazuril crosses the blood/brain barrier to reach the central nervous system (CNS) where it kills the parasite.
- In clinical efficacy trials conducted at equine referral clinics across the country, Marquis was proven effective at the recommended dose level.
- Marquis should effectively clear the horse of S. neurona, but may have no effect on irreparable, pre-existing CNS damage caused by the protozoal parasite prior to treatment.
- The prognosis for animals treated for EPM may be dependent upon the severity of the disease and the duration of infection prior to treatment.
- Early and accurate diagnosis followed by immediate treatment are critical for best clinical response.
- Prescribe with confidence
- Marquis (15% w/w ponazuril) Antiprotozoal Oral Paste offers a wide margin of safety.
- The safe use of this product in horses used for breeding purposes, during pregnancy or in lactating mares, has not been evaluated.
- This product is not for use in animals intended for food.
- Simple administration, shorter regimen
- Formulated in a low-volume paste that horses readily accept.
- Administered once a day for 28 days.
- Simple, low-dose regimen enhances owner compliance.
- Packaged with four syringe barrels and four reusable plungers with a calibrated dosing ring. Each syringe barrel contains enough ponazuril to treat one 1,200-pound horse for seven days. The package contains a complete 28-day treatment regimen.
- A combination of safety, efficacy and convenience in one product
- Cidal activity against Sarcocystis neurona.
- Reaches central nervous system where damage occurs.
- Proven efficacy.
- Wide margin of safety.
- Low dosage volume.
- Short therapy duration.
- Made by Bayer, a world leader of Animal Health products.